Impact Biomedical (IBO) Retained Earnings (2022 - 2026)
Impact Biomedical's (IBO) quarterly Retained Earnings came in at $63.2 million in Q1 2026, up 47.87% YoY from $42.7 million in Q1 2025, and up 227.56% on a QoQ basis from -$49.5 million in Q4 2025.
Impact Biomedical (IBO) Retained Earnings (2022 - 2026) Analysis & Trends
Impact Biomedical (IBO) has 5 years of Retained Earnings data on file, last reported at $63.2 million in Q1 2026.
- Quarterly Retained Earnings rose 47.87% year-over-year to $63.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $63.2 million (up 47.87% YoY) and the FY2025 annual result came in at -$49.5 million, down 31.43% from the prior year.
- Retained Earnings advanced to $63.2 million in Q1 2026, from -$49.5 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $63.2 million in Q1 2026 to a low of -$49.5 million in Q4 2025.
- A 5-year average of $9.7 million and a median of -$8.6 million in 2022 frame the typical range for Retained Earnings.
- The widest YoY moves for Retained Earnings: up 460.78% in 2024, down 190.63% in 2024.
- Tracing IBO's Retained Earnings over 5 years: stood at -$8.6 million in 2022, then tumbled by 50.27% to -$13.0 million in 2023, then slumped by 190.63% to -$37.7 million in 2024, then slumped by 31.43% to -$49.5 million in 2025, then surged by 227.56% to $63.2 million in 2026.
- The last three Retained Earnings figures came in at $63.2 million (Q1 2026), -$49.5 million (Q4 2025), and $42.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | Impact Biomedical | 49.54 Mn | 49.53 Mn | 2,000.00 | 63.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 63.15 Mn |
| Mar 31, 2026 | 63.15 Mn |
| Dec 31, 2025 | -49.51 Mn |
| Sep 30, 2025 | 42.87 Mn |
| Jun 30, 2025 | 42.87 Mn |
| Mar 31, 2025 | 42.71 Mn |
| Dec 31, 2024 | -37.67 Mn |
| Sep 30, 2024 | 41.84 Mn |
| Jun 30, 2024 | 38.11 Mn |
| Mar 31, 2024 | -13.92 Mn |
| Dec 31, 2023 | -12.96 Mn |
| Sep 30, 2023 | -11.67 Mn |
| Jun 30, 2023 | -10.56 Mn |
| Dec 31, 2022 | -8.63 Mn |